Hodgkin’s Lymphoma – Epidemiology – Mature Markets Data
DRG Epidemiology’s coverage of Hodgkin’s lymphoma (HL) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of HL for each country, as well as annualized case counts projected to the national population.
All patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy.
DRG Epidemiology’s HL forecast will answer the following questions:
- Of all people diagnosed with HL, how many in each of the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of HL over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, DRG Epidemiology forecasts seven HLpopulations, as follows:
- Diagnosed incident cases of HL.
- Diagnosed incident cases of classical Hodgkin’s lymphoma (CHL).
- Diagnosed incident cases of nodular lymphocyte-predominant Hodgkin’s lymphoma (NLPHL).
- Diagnosed prevalent cases of CHL.
- Diagnosed prevalent cases of NLPHL.
- Drug-treatable prevalent cases of CHL.
- Drug-treatable prevalent cases of NLPHL.
… and more (details available on request).
Note: Coverage may vary by country.
Table of contents
- Hodgkin's Lymphoma - Epidemiology - Mature Markets Data
- Introduction
- Key Findings
- Incidence of Hodgkin's Lymphoma per 100,000 per Year Among People of All Ages in 2019 and 2039
- Relative Sizes of the Contributing Factors to the Trend in Incident Cases of Hodgkin's Lymphoma over the Next 20 Years
- Analysis of the Incident Cases of Hodgkin's Lymphoma in 2019 by Subtype
- Key Findings
- Epidemiology Data
- Methods
- Lifetime DALYs Gained
- Newly Diagnosed Incidence
- Stage Distribution
- Histological Subtype of Classical Hodgkin's Lymphoma
- Diagnosed Prevalence
- Drug-Treatable Populations
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Hodgkin's Lymphoma
- Studies Excluded from the Analysis of Hodgkin's Lymphoma
- Risk/Protective Factors
- Risk/Protective Factors for Hodgkin's Lymphoma
- Bibliography
- Literature Review
- Introduction
Hannah Sally, M.Sc., is an epidemiologist at DRG, part of Clarivate. She holds a B.Sc. in medical sciences from the University of Leeds and an M.Sc. in public health from the London School of Hygiene and Tropical Medicine. Prior to joining DRG, she worked in medical device clinical research, pharmaceutical industry business intelligence, and a start-up health tech company. As an epidemiologist, she covers multiple disease areas but with a focus on cancer epidemiology.
Nishant Kumar, M.P.H., is a senior director on the Epidemiology team at Clarivate. His areas of expertise are oncology and CNS diseases, including Alzheimer’s disease and dementia. His key interests in oncology are modeling disease progression and drug-treatable incident and prevalent populations. Previously, Mr. Kumar sized patient populations for rare and niche diseases, such as graft-versus-host disease and Duchenne muscular dystrophy. He earned his M.P.H. with a concentration in epidemiology and statistics from King’s College in London and a B.Sc. (Honors) in medical studies from the University of Birmingham.